
Human ADP-dependent glucokinase 299-307, ASMTNMELM
Description
About Human ADP-dependent glucokinase 299-307, ASMTNMELM
The Human ADP-dependent glucokinase (mutated sequence of ASMTNRELM) Peptide (IEDB: 1074356) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The ADP-dependent glucokinase Peptide, H-ASMTNMELM-OH (Uniprot: Q9BRR6 aa: 299-307) from JPT is produced under strict quality control and quality management.
Human ADP-dependent glucokinase 299-307, ASMTNMELM - Specifications
- Peptide sequence: H-ASMTNMELM-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human ADP-dependent glucokinase 299-307, ASMTNMELM
References:
Read References with JPT’s Antigen Peptides
Human ADP-dependent glucokinase 299-307, ASMTNMELM has been described in:
Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy., Nat Commun, 2017 (PMID: 29133898)
The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice., Cancer Immunol Immunother, 2020 (PMID: 32561966)
Documentation
Documentation for Human ADP-dependent glucokinase 299-307, ASMTNMELM
Properties
Properties of Human ADP-dependent glucokinase 299-307, ASMTNMELM
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | ADP-dependent glucokinase |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human ADP-dependent glucokinase 299-307, ASMTNMELM
Information | Values |
---|---|
Sequence: | H-ASMTNMELM-OH |
WT Sequence: | ASMTNRELM |
Specifications: | 9mer peptide as TFA salt |